Immunotherapy Drug Nivolumab Increases Survival Rate Of Melanoma Patients By Up To Five Years Nivolumab was shown to increase the five-year survival rate of patients with melanoma. The immunotherapy drug showed this promising result during its phase I clinical trial. by Rina Marie Doctor
Healthy Living/Wellness Ill Soldier Blames Army Not Issuing Sun Cream For His Skin Cancer by Katrina Pascual
Healthy Living/Wellness FDA Declines Approval Of Opdivo Drug For Expanded Use As Metastatic Melanoma Treatment by Katherine Derla
Healthy Living/Wellness Jimmy Carter Battles Metastatic Melanoma: New Cancer Drugs And Treatment Give Hope To Ex-President by Rhodi Lee
Healthy Living/Wellness Bristlo-Myers advanced melanoma drug Nivolumab ups survival rate during trial by Anne Francis